What is B. Riley’s Forecast for KYMR FY2025 Earnings?

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Research analysts at B. Riley issued their FY2025 EPS estimates for Kymera Therapeutics in a research report issued on Monday, March 3rd. B. Riley analyst K. Patel forecasts that the company will post earnings per share of ($3.95) for the year. The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.79) per share. B. Riley also issued estimates for Kymera Therapeutics’ FY2026 earnings at ($4.46) EPS, FY2027 earnings at ($5.62) EPS and FY2028 earnings at ($5.82) EPS.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.12). The business had revenue of $7.39 million during the quarter, compared to analyst estimates of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%.

A number of other equities research analysts have also recently issued reports on KYMR. BTIG Research initiated coverage on Kymera Therapeutics in a research note on Tuesday, December 10th. They set a “buy” rating and a $60.00 price objective on the stock. BMO Capital Markets initiated coverage on shares of Kymera Therapeutics in a research report on Friday, December 6th. They set a “market perform” rating and a $55.00 price target on the stock. Wells Fargo & Company raised shares of Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $38.00 to $57.00 in a research report on Monday, December 2nd. HC Wainwright upped their target price on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a “buy” rating in a report on Friday, February 28th. Finally, Leerink Partners reiterated an “outperform” rating and issued a $60.00 target price on shares of Kymera Therapeutics in a research note on Friday, December 27th. Three investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Kymera Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $56.69.

Kymera Therapeutics Stock Performance

KYMR opened at $32.54 on Wednesday. The business’s 50-day simple moving average is $38.23 and its 200 day simple moving average is $43.40. Kymera Therapeutics has a 52-week low of $29.07 and a 52-week high of $53.27. The firm has a market capitalization of $2.11 billion, a PE ratio of -13.91 and a beta of 2.22.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, insider Ellen Chiniara sold 3,129 shares of Kymera Therapeutics stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $41.75, for a total value of $130,635.75. Following the completion of the sale, the insider now owns 54,826 shares in the company, valued at $2,288,985.50. The trade was a 5.40 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Jeremy G. Chadwick sold 1,383 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $42,112.35. Following the transaction, the chief operating officer now directly owns 67,800 shares in the company, valued at $2,064,510. This represents a 2.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 13,788 shares of company stock worth $455,202 in the last ninety days. 15.82% of the stock is owned by company insiders.

Institutional Investors Weigh In On Kymera Therapeutics

Several institutional investors have recently made changes to their positions in KYMR. Wellington Management Group LLP lifted its position in shares of Kymera Therapeutics by 14.9% during the 4th quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company’s stock valued at $213,514,000 after acquiring an additional 688,967 shares during the period. Avoro Capital Advisors LLC raised its stake in Kymera Therapeutics by 14.4% in the fourth quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company’s stock valued at $207,184,000 after purchasing an additional 650,000 shares in the last quarter. Deerfield Management Company L.P. Series C acquired a new stake in Kymera Therapeutics during the fourth quarter worth about $23,856,000. Boxer Capital Management LLC acquired a new stake in Kymera Therapeutics during the fourth quarter worth about $17,098,000. Finally, Jennison Associates LLC raised its position in shares of Kymera Therapeutics by 85.8% in the 3rd quarter. Jennison Associates LLC now owns 797,681 shares of the company’s stock valued at $37,754,000 after buying an additional 368,394 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.